The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1
Open accessAbstract
Apolipoprotein L1 (APOL1) risk variants greatly elevate the risk of kidney disease in African Americans. Here we report a cohort of patients who developed collapsing focal segmental glomerulosclerosis while receiving therapeutic interferon, all of whom carried the APOL1 high-risk genotype. This finding raised the possibility that interferons and the molecular pattern recognition receptors that stimulate interferon production may contribute to APOL1-associated kidney disease. In cell culture, interferons and toll-like receptor agonists increased APOL1 expression by up to 200-fold, in some cases with the appearance of transcripts not detected under basal conditions. PolyI:C, a double-stranded RNA TLR3 agonist, increased APOL1 expression by upregulating interferons directly or through an interferon-independent, IRF-3 dependent pathway. Using pharmacological inhibitors, shRNA knockdown, and chromatin immunoprecipitation, we found that the interferon-independent TLR3 pathway relied on signaling through TBK1, NF-kB, and Jak kinases, and on binding of IRF1, IRF2, and STAT2 at the APOL1 transcription start site. We also demonstrate that overexpression of the APOL1 risk variants is more injurious to cells than overexpression of the wild-type APOL1 protein. Our study illustrates that anti-viral pathways may be an important inducer of kidney disease in individuals with the APOL1 high-risk genotype and identifies potential targets for prevention or treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
Genovese, G., Friedman, D. J., Ross, M. D., Lecordier, L., Uzureau, P., Freedman, B. I., Bowden, D. W., Langefeld, C. D., Oleksyk, T. K., Uscinski Knob, A. L., et al. (2010) · Science · doi:10.1126/science.1193032 · Cited by 2,028
Self-citationAPOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy
Kopp, J. B., Nelson, G. W., Sampath, K., Johnson, R. C., Genovese, G., An, P., Friedman, D., Briggs, W., Dart, R., Korbet, S., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040388 · Cited by 855
Self-citationPeroxisomes Are Signaling Platforms for Antiviral Innate Immunity
Dixit, E., Boulant, S., Zhang, Y., Lee, A. S. Y., Odendall, C., Shum, B., Hacohen, N., Chen, Z. J., Whelan, S. P., Fransen, M., et al. (2010) · Cell · doi:10.1016/j.cell.2010.04.018 · Cited by 817
ENCODE Data in the UCSC Genome Browser: year 5 update
Rosenbloom, K. R., Sloan, C. A., Malladi, V. S., Dreszer, T. R., Learned, K., Kirkup, V. M., Wong, M. C., Maddren, M., Fang, R., Heitner, S. G., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1172 · Cited by 766
Tzur, S., Rosset, S., Shemer, R., Yudkovsky, G., Selig, S., Tarekegn, A., Bekele, E., Bradman, N., Wasser, W. G., Behar, D. M., et al. (2010) · Human Genetics · doi:10.1007/s00439-010-0861-0 · Cited by 653
A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection
Shapira, S. D., Gat-Viks, I., Shum, B. O. V., Dricot, A., de Grace, M. M., Wu, L., Gupta, P. B., Hao, T., Silver, S. J., Root, D. E., et al. (2009) · Cell · doi:10.1016/j.cell.2009.12.018 · Cited by 635
Apolipoprotein L-I is the trypanosome lytic factor of human serum
Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D. P., Lins, L., Van Den Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., et al. (2003) · Nature · doi:10.1038/nature01461 · Cited by 500
Reilly, S. M., Chiang, S.-H., Decker, S. J., Chang, L., Uhm, M., Larsen, M. J., Rubin, J. R., Mowers, J., White, N. M., Hochberg, I., et al. (2013) · Nature Medicine · doi:10.1038/nm.3082 · Cited by 433
Clark, K., Plater, L., Peggie, M., & Cohen, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000414 · Cited by 385
Toll-Like Receptors and RNA Helicases: Two Parallel Ways to Trigger Antiviral Responses
Meylan, E., & Tschopp, J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.012 · Cited by 372
O'Neill, L. A. J. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.004 · Cited by 330
End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1
Freedman, B. I., Langefeld, C. D., Andringa, K. K., Croker, J. A., Williams, A. H., Garner, N. E., Birmingham, D. J., Hebert, L. A., Hicks, P. J., Segal, M. S., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38220 · Cited by 299
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Quintás-Cardama, A., Kantarjian, H., Cortes, J., & Verstovsek, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3264 · Cited by 290
APOL1 Localization in Normal Kidney and Nondiabetic Kidney Disease
Madhavan, S. M., O'Toole, J. F., Konieczkowski, M., Ganesan, S., Bruggeman, L. A., & Sedor, J. R. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011010069 · Cited by 239
Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas
Duchateau, P. N., Pullinger, C. R., Orellana, R. E., Kunitake, S. T., Naya-Vigne, J., O'Connor, P. M., Malloy, M. J., & Kane, J. P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25576 · Cited by 227
Population-Based Risk Assessment of APOL1 on Renal Disease
Friedman, D. J., Kozlitina, J., Genovese, G., Jog, P., & Pollak, M. R. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050519 · Cited by 226
Self-citationTreatment with IFN-α, -β, or -γ Is Associated with Collapsing Focal Segmental Glomerulosclerosis
Markowitz, G. S., Nasr, S. H., Stokes, M. B., & D'Agati, V. D. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07311009 · Cited by 221
Self-citationLarsen, C. P., Beggs, M. L., Saeed, M., & Walker, P. D. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012121180 · Cited by 207
Human Trypanosoma evansi Infection Linked to a Lack of Apolipoprotein L-I
Vanhollebeke, B., Truc, P., Poelvoorde, P., Pays, A., Joshi, P. P., Katti, R., Jannin, J. G., & Pays, E. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063265 · Cited by 187
Sudbeck, E. A., Liu, X., Narla, R. K., Mahajan, S., Ghosh, S., Mao, C., & Uckun, F. M. (1999) · PubMed · Cited by 164
Smith, E. E., & Malik, H. S. (2009) · Genome Research · doi:10.1101/gr.085647.108 · Cited by 161
Monajemi, H., Fontijn, R. D., Pannekoek, H., & Horrevoets, A. J. G. (2002) · Genomics · doi:10.1006/geno.2002.6729 · Cited by 160
ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death
Zhaorigetu, S., Wan, G., Kaini, R. R., Wan, G., Jiang, Z., & Hu, C. A. (2008) · Autophagy · doi:10.4161/auto.7066 · Cited by 148
The Human Apolipoprotein L Gene Cluster: Identification, Classification, and Sites of Distribution
Page, N., Butlin, D., Lomthaisong, K., & Lowry, P. J. (2001) · Genomics · doi:10.1006/geno.2001.6534 · Cited by 143
Genetics of kidney failure and the evolving story of APOL1
Friedman, D. J., & Pollak, M. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46263 · Cited by 138
Self-citationDuchateau, P. N., Pullinger, C. R., Cho, M., Eng, C. S., & Kane, J. P. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31171-8 · Cited by 134
APOL1 Null Alleles from a Rural Village in India Do Not Correlate with Glomerulosclerosis
Johnstone, D. B., SHEGOKAR, V. R., Nihalani, D., Rathore, Y. S., Mallik, L., Ashish, ZARE, V. R., Ikizler, H. O., POWAR, R. M., & Holzman, L. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051546 · Cited by 89
JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy
Divers, J., Núñez, M., High, K. P., Murea, M., Rocco, M. V., Ma, L., Bowden, D. W., Hicks, P. J., Spainhour, M. H., Ornelles, D. A., et al. (2013) · Kidney International · doi:10.1038/ki.2013.173 · Cited by 70
IFN-α Sensitizes Human Umbilical Vein Endothelial Cells to Apoptosis Induced by Double-Stranded RNA
Kaiser, W. J., Kaufman, J. L., & Offermann, M. K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1699 · Cited by 64
Goodman, P. A., Niehoff, L. B., & Uckun, F. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17742 · Cited by 55
Cited by
Focal Segmental Glomerulosclerosis
Rosenberg, A. Z., & Kopp, J. B. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05960616 · Cited by 562
Self-citationTransgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice
Beckerman, P., Bi-Karchin, J., Park, A. S. D., Qiu, C., Dummer, P. D., Soomro, I., Boustany-Kari, C. M., Pullen, S. S., Miner, J. H., Hu, C.-A. A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4287 · Cited by 344
Self-citationAPOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans
Kasembeli, A. N., Duarte, R., Ramsay, M., Mosiane, P., Dickens, C., Dix-Peek, T., Limou, S., Sezgin, E., Nelson, G. W., Fogo, A. B., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014050469 · Cited by 326
Self-citationThe next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
APOL1 Nephropathy: From Genetics to Clinical Applications
Friedman, D. J., & Pollak, M. R. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15161219 · Cited by 270
Self-citation
Metadata
- Authors
- Nichols, B., Jog, P., Lee, J. H., Blackler, D., Wilmot, M., D'Agati, V., Markowitz, G., Kopp, J. B., Alper, S. L., Pollak, M. R., & Friedman, D. J.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 87
- Issue
- 2
- Pages
- 332-342
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2092001580
- Cited by
- 355
- References
- 31
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.